Novo Nordisk: EU approves new type 2 diabetes treatment
(CercleFinance.com) - The European Commission has approved Novo Nordisk's Ozempic for the treatment of adults with type 2 diabetes, the Danish firm said on Friday.
The marketing authorisation for the new once-weekly analogue of human glucagon-like peptide-1 applies to all 28 European Union member states, the drugmaker added.
"We believe it has the potential to set a new standard for the treatment of type 2 diabetes," said Mads Krogsgaard Thomsen, Novo's chief science officer.
The drug had already been approved by the US FDA in December 2017.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The marketing authorisation for the new once-weekly analogue of human glucagon-like peptide-1 applies to all 28 European Union member states, the drugmaker added.
"We believe it has the potential to set a new standard for the treatment of type 2 diabetes," said Mads Krogsgaard Thomsen, Novo's chief science officer.
The drug had already been approved by the US FDA in December 2017.
Copyright (c) 2018 CercleFinance.com. All rights reserved.